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Introduction 
Peptides and proteins play a variety of important roles for diverse biological functions and 
due to an extensive progress in the biotechnological area it is now possible to produce a high 
number of potential therapeutic peptide and protein drugs. Oral dosage forms are preferred 
when taking patient compliance into consideration; however, oral delivery of peptide and 
protein drugs constitutes a number of challenges due to the large molecular size, enzymatic 
instability and poor membrane permeability of the molecules. To overcome the poor 
membrane permeability, the use of cell penetrating peptides (CPP’s) are of great interest [1] 
as they have shown potential in improving the transepithelial transport of therapeutic 
peptides upon co-administration [2] or direct conjugation [3]. Of these two methodologies, co-
administration is generally preferred due to a possibly better protection of the biological 
activity of the drug and ease in sample preparation, whereas a drawback is the possible 
generation of poorly characterized complexes when simply mixing the CPPs with the 
therapeutic peptides.  
Knowledge is however lacking regarding the effect on the biological activity of the therapeutic 
peptide or protein and the cell penetrating propensity of the CPP as a result of direct 
conjugation; an issue addressed in the present study. Hence, the objective of this study is to 
produce a number of fusion peptides comprising the biologically active part of parathyroid 
hormone (PTH1-34) coupled to the CPPs penetratin (Pen), the HIV-1 Transactivating (Tat) 
protein, the HSV-1 structural protein VP22 or nonaarginine (R9). These fusion peptides have 
been characterized according to secondary structure, which is thought to be relevant for the 
potency of PTH1-34 and the cell penetrating propensity of the CPPs [4].  
 
Results and Discussion 
PTH1-34 and 7 CPP-coupled PTH1-34 (Fig. 1) fusion peptides have been expressed and 
purified employing a newly developed protocol for the expression and purification of insoluble 
inclusion bodies (IBs). Briefly, DNA constructs were cloned into a His-tag vector using ligase-
independent cloning and expressed in E. coli as IBs. The IBs were solubilized in 6M 
guanidinium and subjected to affinity chromatography followed by reverse phase (RP) HPLC 
for purification. The His-tag was removed by incubation with a TEV protease (Fig. 2a) and 
separated from the fusion peptides by RP-HPLC (Fig. 2b). Molecular weights were verified 
by mass spectrometry (MS) (Fig. 2c).  
 
 
Figure 1. Model illustrating the N- and C-terminally CPP-coupled PTH1-34 fusion peptides, which are 
expressed and purified from IBs. 
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Figure 2. Representative purification of Tat-PTH1-34 after cleavage of the His-tag (a), separation of 
the His-tag from Tat-PTH1-34 by RP-HPLC (b) and verification of the molecular weight by MS (c).  
The secondary structure of PTH1-34 and the PTH1-34 fusion peptides was analysed by 
circular dicroism (CD) spectroscopy (Fig. 3) in the absence or presence of trifluoroethanol 
(TFE), which is widely used as an α-helix promoting agent. Without TFE, PTH1-34 and the 
fusion peptides lacked secondary structure (Fig. 3a), but with TFE the α-helical content 
increased as observed by a shift towards minima at 208 nm and 222 nm (Fig. 3b). Whether 
the CPP was N- or C-terminally coupled to PTH1-34, only affected the spectra of the Tat 
conjugated PTH1-34 when TFE was present. This indicates that the specific N- or C-terminal 
positioning of Tat might affect the potency of PTH1-34 and the cell penetrating propensity of 
Tat, as an α-helical content is important for receptor binding and interaction with the plasma 
membrane, respectively. 
 
Figure 3. CD spectra of 10 µM PTH1-34 or 10 µM CPP-modified PTH1-34 fusion peptides in the 
absence (a) or presence (right) of 20% TFE.   
Conclusion 
PTH1-34 and N- or C-terminally CPP-coupled PTH1-34 fusion peptides were succesfully 
expressed and purified from IBs. CD spectra revealed a disordered secondary structure in 
buffer, but with TFE added the α-helical content increased in all peptides. A difference in α-
helical content as a result of N- or C-terminal coupling of CPP was only observed for the Tat-
coupled PTH1-34 indicating that the specific N- or C-terminal positionning of Tat might be of 
relevance for membrane pertubation and receptor activation.  
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